Zacks: Analysts Expect Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Will Announce Earnings of -$1.29 Per Share

Analysts expect Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCTGet Rating) to announce earnings of ($1.29) per share for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Arcturus Therapeutics’ earnings, with the highest EPS estimate coming in at ($1.02) and the lowest estimate coming in at ($1.76). Arcturus Therapeutics posted earnings of ($2.15) per share during the same quarter last year, which would suggest a positive year over year growth rate of 40%. The business is expected to issue its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Arcturus Therapeutics will report full-year earnings of ($4.59) per share for the current year, with EPS estimates ranging from ($7.44) to $0.13. For the next fiscal year, analysts expect that the firm will report earnings of $4.23 per share, with EPS estimates ranging from ($7.04) to $14.29. Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Arcturus Therapeutics.

Arcturus Therapeutics (NASDAQ:ARCTGet Rating) last released its earnings results on Monday, February 28th. The biotechnology company reported ($1.47) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.77) by $0.30. The company had revenue of $5.79 million during the quarter, compared to the consensus estimate of $12.90 million. Arcturus Therapeutics had a negative net margin of 1,647.99% and a negative return on equity of 61.88%. During the same quarter in the previous year, the firm earned ($1.25) EPS.

Several analysts have weighed in on the company. Cantor Fitzgerald cut their target price on Arcturus Therapeutics from $93.00 to $86.00 in a research note on Tuesday, March 1st. Barclays cut their price target on shares of Arcturus Therapeutics from $31.00 to $21.00 in a report on Tuesday, March 1st. HC Wainwright decreased their target price on Arcturus Therapeutics from $47.00 to $25.00 in a report on Tuesday, March 1st. StockNews.com initiated coverage on shares of Arcturus Therapeutics in a research note on Thursday, March 31st. They set a “sell” rating for the company. Finally, Wells Fargo & Company decreased their target price on Arcturus Therapeutics from $107.00 to $105.00 and set an “overweight” rating for the company in a research report on Friday, March 25th. Six investment analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $43.63.

Shares of NASDAQ:ARCT traded down $1.33 during trading on Friday, hitting $21.26. 525,108 shares of the company traded hands, compared to its average volume of 584,918. Arcturus Therapeutics has a one year low of $16.93 and a one year high of $65.00. The business’s fifty day moving average is $24.29 and its 200-day moving average is $32.28. The stock has a market capitalization of $560.73 million, a price-to-earnings ratio of -2.75 and a beta of 2.74.

Institutional investors have recently modified their holdings of the business. Allspring Global Investments Holdings LLC acquired a new stake in Arcturus Therapeutics in the fourth quarter worth about $32,000. KRS Capital Management LLC bought a new position in shares of Arcturus Therapeutics during the 4th quarter valued at about $51,000. Daiwa Securities Group Inc. increased its stake in Arcturus Therapeutics by 4,487.0% during the 3rd quarter. Daiwa Securities Group Inc. now owns 2,110 shares of the biotechnology company’s stock worth $101,000 after purchasing an additional 2,064 shares in the last quarter. Byrne Asset Management LLC raised its holdings in Arcturus Therapeutics by 29.4% during the 1st quarter. Byrne Asset Management LLC now owns 4,000 shares of the biotechnology company’s stock worth $108,000 after buying an additional 910 shares during the period. Finally, Point72 Hong Kong Ltd bought a new stake in shares of Arcturus Therapeutics during the third quarter worth $116,000. 76.86% of the stock is currently owned by hedge funds and other institutional investors.

About Arcturus Therapeutics (Get Rating)

Arcturus Therapeutics Holdings Inc, an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU.

Read More

Get a free copy of the Zacks research report on Arcturus Therapeutics (ARCT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Arcturus Therapeutics (NASDAQ:ARCT)

Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.